NRC HEALTH (NRC) stock intrinsic value fair value estimate & owner earnings analysis

NRC Health (National Research Corporation, Lincoln, Nebraska, founded 1981) sells subscription survey, analytics and workflow software to U.S. hospitals and health systems in four groups: Patient Experience (including regulatory CAHPS patient surveys), Consumer Experience, Employee Experience and Market Experience (its Market Insights survey covers about 300,000 healthcare consumers a year). It also runs a healthcare-governance membership network for hospital boards. Revenue is recurring and contract-based, but the market is concentrated: its two main rivals, Press Ganey and Qualtrics, are far larger, and Qualtrics completed its $6.75 billion purchase of Press Ganey Forsta in May 2026, putting both under one owner. Its ten largest customers rose from 15% of revenue in 2023 to 20% in 2025. What the business earns. We measure owner earnings as operating cash flow, minus working-capital swings, stock compensation and the capital spending needed to stay in business. On that basis owner earnings rose from $21.9M (2016) to about $39-41M in 2020-2021 ($1.53-$1.59 per share), then fell each year to $11.5M ($0.51 per share) in 2025. Two things drove the fall. Revenue peaked at $151.6M in 2022 and slid to $137.4M in 2025 as existing customers bought less. Capital spending jumped from about $4-6M a year to $15.8M in 2023 and $15.4M in 2024 (software development for its Human Understanding platform, plus a headquarters renovation finished in June 2025). Because revenue was falling, we count all of that spending as a cost of staying in business rather than as growth investment. Amortization of acquired intangibles is small ($0.4M in 2025), so no wasting asset needs special handling. Debt. The company now borrows to pay dividends and buy back stock. In 2025 it spent $20.2M on buybacks and $11.0M on dividends against $11.5M of owner earnings, and raised the quarterly dividend from $0.12 to $0.16 starting January 2026. Gross bank debt was about $90.3M at June 30, 2026 (a $110M delayed-draw term loan due February 6, 2030, plus a $30M revolver due February 6, 2028), against $3.3M of cash. Book equity fell to $6.5M. The loans float at SOFR plus 2.25-2.75% (6.22% at year-end 2025), close to our 6% discount rate, so we make no adjustment for the cost of the debt. The covenants require a fixed-charge coverage of at least 1.10x and leverage of at most 3.50x, and the company was in compliance at year-end 2025. So we value the business before its interest payments and then subtract the $90.3M (about $4.07 per share on roughly 22.2M shares). Cash interest paid was $4.5M in 2025. Starting level. Before interest, the business produced $30.0M in 2022, $21.2M in 2023, $17.5M in 2024 and $16.0M in 2025. We use 2022-2025 because this is the business as it now stands: after the revenue peak, during the platform rebuild and under new leadership. The 2025 figure includes $6.6M of one-time cash bonuses tied to the leadership transition (Trent Green, formerly CEO of Amazon One Medical, became CEO on June 1, 2025). Adding those back after tax lifts 2025 to about $21M. The median of the four years is about $0.90 per share, or roughly $20M a year. Recent quarters are mixed. TRCV is the company's measure of contracted renewable revenue expected over the next twelve months. It rose from $133.2M at end-2024 to $144.1M at end-2025, $152.0M in March 2026 and $151.9M at June 30, 2026 (+11% year over year), and first-half 2026 revenue was up 3.9%. First-half capital spending fell to $3.2M from $6.0M a year earlier. On the other hand, the second quarter of 2026 showed a $3.3M net loss, after a $7.4M non-cash charge from accelerated executive stock vesting and $3.2M of further transition costs. These so-called one-time leadership costs have now appeared in two straight years. Growth check. In 2025, before-interest cash flow per share fell 3.2% (owner earnings per share fell 19%). The base case assumes +3% in year one. We assume a reversal because contracted renewable revenue (TRCV) was 11% higher at June 30, 2026 than a year before, and first-half 2026 revenue was already growing. Bear case ($2.08 per share). This case starts from the unadjusted 2025 level of about $15.8M and assumes leadership and restructuring costs keep recurring. The recent contract gains fade the way TRCV fell 6% in 2024, and revenue goes back to declining about 3% a year, as it did in 2022-2025, against a larger combined Press Ganey-Qualtrics. With mostly fixed costs, cash flow falls 5% a year with no recovery. The business is worth about $137M and owes $90M, leaving about $46M. Interest stays covered, but the dividend would probably have to be cut to keep within the covenants and to refinance the 2030 term loan. Base case ($9.48 per share). Cash flow rises about 3% a year in 2026 and 2027, supported by the contracted TRCV gains, and then holds flat through 2035. We credit no further growth because the business has not shown it can keep growing against its larger rivals. After 2035 cash flow declines 2% a year. Two things support continued earnings: regulators require CAHPS patient surveys, and the company has customer relationships going back decades. Two things argue for slow erosion: the 2022-2025 revenue decline and rising customer concentration. The business is worth about $301M and owes $90M, leaving about $210M. Bull case ($17.73 per share). The TRCV gains turn into revenue, capital spending stays near the first-half-2026 pace, and the transition costs end. Cash flow rises to about $26.6M by 2028, near its 2022 level. It then grows 2% a year, below the roughly 5-6% annual revenue growth of 2015-2022, which came from new products and small acquisitions. It reaches about $30.6M by 2035 (about $1.38 per share, below the 2020-2021 peak) and holds flat after that. The business is worth about $484M and owes $90M, leaving about $394M. Margin-of-safety price. The range is wide: the bear value is less than a quarter of the base value, and debt magnifies any shortfall. The base value of $9.48 is only a median outcome. From $6.00, if the base case plays out over about three years, the rise toward roughly $9.50 plus about $0.64 a year in dividends implies roughly a 20% annual return. It also leaves room for weaker results than the base case. The margin-of-safety price is set no higher than $6.00, because the bear case shows the value can fall well below this if customer losses resume. Changes since our previous analysis. Our earlier estimates were $0.05 / $4.77 / $13.52 with a $9.50 margin-of-safety price that depended on owner earnings recovering. We now discount every case at one 6% rate and put the risk into the cases themselves. We start from a normalized multi-year level rather than the depressed 2025 year, and we value the business before debt and then subtract it. That raises all three values. New facts since then cut both ways. Contracted TRCV reached $151.9M, capital spending is falling, and the Press Ganey-Qualtrics merger is now complete. Debt rose to about $90M, the Q2 2026 loss was driven by executive pay, and our assumed growth is lower than before. What would make this wrong: TRCV falling back, more large customers lost to the combined Press Ganey-Qualtrics, or capital spending returning to $15M a year.